Abstract 9P
Background
Breast cancer is identified as a leading cancer in Kyrgyz females. Poor diagnostic approaches lead to high rate of advanced breast cancer cases and consequently to a high mortality rate. Genetic testing is a promising method of prevention and early diagnosis of breast cancer.
Methods
This was a case-control study of 201 women of the Kyrgyz ethnic group with a morphologically verified breast cancer (N=99) and 102 controls age-matched with BC cases. The mean age of the patients was 48 years (minimum 24, maximum 74, STD=9.83). The extraction of DNA was carried out from venous blood. The genotyping was performed by using restriction fragment length polymorphism assay.
Results
Genotype CT of the polymorphic variant V353A HMMR gene has been defined as protective factor and decreases the risk of developing of breast cancer in the Kyrgyz population (OR=0,481, 95%CI 0,272 – 0,850, р=0,011). As well as combinations of the allele 194Trp (XRCC1 Arg194Trp) and genotype СТ (HMMR V353A) (OR=0,302, [95% CI 0,128-0,713], р=0,005), CT/TT (OR=0,459, 95% CI [0,259-0,814], р=0,007) of HMMR V353A and Palb2 T1100T (3300T>G)polymorphisms, CT/GG (OR=0,546, 95% CI [0,298-0,999], р=0,048) of HMMR V353A and TNF aG3080A polymorphisms are associated with decreased risk of developing of breast cancer in the Kyrgyz ethnic group. Furthermore, the allele 194Trp is associated with late age of diagnosis of breast cancer when comparing to 194Arg allele of XRCC1 gene (p=0,017), more often occurs in postmenopausal women (p=0,005) and in women with high BMI (>25) (p=0,003).
Conclusions
The above genotypes may be used as markers for evaluation of the risk of breast cancer in the Kyrgyz ethnic group.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
184P - Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression
Presenter: Jun Ji
Session: Poster display session
Resources:
Abstract
185P - Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis
Presenter: Yang Yuan
Session: Poster display session
Resources:
Abstract
187P - Correlation between spleenic dose and grade of hematological toxicity in chemoradiation of stomach
Presenter: Umesh Velu
Session: Poster display session
Resources:
Abstract
188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience
Presenter: Sonngwit Payapwattanawong
Session: Poster display session
Resources:
Abstract
189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastatis to liver: A single Institution experience
Presenter: Sayan Paul
Session: Poster display session
Resources:
Abstract
190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
Presenter: Yusuke Nagata
Session: Poster display session
Resources:
Abstract
191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients
Presenter: Noha El Baghdady
Session: Poster display session
Resources:
Abstract
192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients
Presenter: Anvesh Rathore
Session: Poster display session
Resources:
Abstract